We’re Looking at Healthcare All Wrong: Part 2

What you’ll learn:

There is so much discussion about the problems facing healthcare—and there are so many people and organizations responsible for pulling it in different directions. From the people responsible for delivering it to the people responsible for paying for it to the individuals and families receiving it, there doesn't seem to be consensus on what "good" looks like and on how we define value within the system.

What is valuable is largely determined by perspective.

In We’re Looking at Healthcare All Wrong, John Guarino shares how decisions that are rational for each stakeholder can still produce unintended outcomes at the system level. Clinical benefit is real but interpreted differently depending on who bears risk. Economic impact exists but is often captured by someone other than the innovator. Experience matters to patients and clinicians, yet is rarely priced explicitly. Total cost is carried by payers, employers, and the government, often disconnected from where benefit shows up. Time horizons almost never align.

This series examines healthcare by changing seats and explores how structure shapes behavior, why accountability fractures across settings, and what it would take to move from stakeholder optimization to shared ownership of outcomes.

I’ve spent years discussing value in healthcare with stakeholders across the industry. We model it. We quantify it. We argue about thresholds and trade-offs. We refine definitions until they feel precise.

And then I listened to patients.

What I hear is not a theory of value. It is something far simpler, and far more unforgiving: “I just want to get better without losing my house.”

The longer I’ve observed the system, the more I’ve realized this is not an emotional statement, it is an evaluative one. This is how patients define value. 

When we use terms like “clinical benefit,” we usually mean endpoints. When patients say it, they mean something immediate and personal: Do I feel better? Will I live longer? Can I live normally? 

For them, “symptom relief” determines whether someone can get through the day. “Survival” is hope measured in time—more birthdays, more stability, fewer crises. “Quality of life” is the ability to function, to work, to care for family, and to preserve dignity. 

From the patient’s perspective, these dimensions collapse into a single question: “Is this helping me live the life I want?”

When Financial Reality Enters the Equation

This is where value begins, but it doesn’t stay there. Patients rarely think about cost until they absolutely have to or until they’re told they should be outraged by it. The financial architecture of healthcare operates invisibly at first: rebates, contracting, employer contributions, and actuarial assumptions. Patients do not wake up thinking about the negotiated net price. 

Then the deductible resets. 

A co-pay spikes. 

A coinsurance percentage becomes a four-figure bill. 

A prior-authorization delays a recommended therapy. 

The invisible becomes personal.

I’ve watched that shift happen. Clinical questions give way to financial ones, not because patients care less about outcomes, but because out-of-pocket exposure has become an outcome in itself. 

We describe cost-sharing as a financing mechanism, but cost doesn’t just accompany care—it alters it. It shapes behavior. Patients delay refills to bridge pay cycles and skip follow-up visits because they fear the financial impact. I’ve seen them choose “covered” options over clinically preferred ones—not out of distrust, but because they prioritize financial stability. These decisions are not irrational, they are trade-offs that reflect the realities of the patients’ lived experience.

Friction, Access, and the Lived Experience of Care

Patients perceive care as a single story. The system delivers it as a sequence of approvals, forms, networks, handoffs, and benefit rules. When access to care is delayed, value declines before treatment begins. When processes are complex, friction accumulates. When incentives appear misaligned, trust erodes. When navigation support is absent, continuity breaks. While elements may seem individually manageable, patients experience them cumulatively—they determine whether care feels possible.

Total cost introduces a final distortion. When we speak of the total cost of care, we mean aggregate system spending. Patients interpret this as something narrower and more consequential: What will this cost me? Deductibles create shock. Coinsurance becomes a steady drain. Coverage variability introduces uncertainty and financial anxiety follows. Even clinically transformative therapies can still feel unaffordable. When out-of-pocket exposure is tied to list price rather than net price, patients perceive value as the bill they receive, a visible number, and not the negotiated one.

The time horizon compounds all of this. While health plans operate on an annual cycle, patients do not. They experience disease immediately, symptoms today, bills this month, while consequences unfold over years. Immediate cost competes with future benefit. Short-term discomfort competes with long-term survival. When benefit structures prioritize short-term budget predictability at the expense of continuity, patients feel that tension directly.

Value Is Filtered by Structure, Not Just Proven Clinically

Over time, I’ve come to see that this distortion isn’t accidental. Coverage design and access pathways do not align with clinical value—they mediate it. We speak as though value is inherent to the therapy, embedded in the molecule and proven in the trial. But patients never experience the molecule in isolation, they experience it through deductibles, prior authorizations, formulary tiers, network restrictions, and coinsurance tied to prices they did not negotiate.

In theory, clinical benefit is objective, in practice, it is filtered.

If authorization delays therapy, the benefit is postponed. If cost-sharing is high, adherence becomes conditional. If coverage resets annually, continuity becomes fragile. While none of this eliminates efficacy, it reshapes perceived value. Patients focus not on “Does it work?” but “Can I access it, sustain it, and survive it financially?” Coverage and cost-sharing were designed to manage utilization and spending. That logic may be rational at the system level. From the patient’s perspective, they are gatekeepers to benefit, and gatekeeping changes behavior. It delays initiation, fragments adherence, and introduces trade-offs that were never part of the clinical conversation. 

These are not unfortunate accidents, they are signs that the system is working exactly as designed.

The Misalignment and the Mandate to Change 

The misalignment is structural. We measure value at the population level while patients experience it at the household level. Until those vantage points converge, perceived value will remain unstable, even when clinical innovation is strong.

Patients are not trying to optimize actuarial models, they are trying to navigate disease without financial collapse. When they say, “I’m just trying to get better without losing my house,” they are not rejecting value frameworks, they are redefining them. If we are serious about alignment, we must decide whether our structures will continue to filter clinical benefit or finally protect it.

Klick Health is the world’s largest independent commercialization partner for life sciences and a leading full-service pharma marketing partner, serving as agency of record for leading pharma, biotech, and healthcare brands. Klick’s specialized offerings are rooted in deep medical and scientific understanding, including market insights, award-winning creative, and proprietary AI and data models to craft impactful brand narratives and seamless customer journeys. Backed by nearly 250 medical experts and advanced healthcare analytics, Klick delivers integrated marketing strategy and communications, from new product launch strategy to MLR review with real-world evidence, helping brands thrive in today’s complex healthcare landscape. Learn more at Klick.com.